Hematopoietic Stem Cell Transplantation in China
Overview
Hematopoietic stem-cell transplantation replaces a patient’s blood-forming system after high-dose therapy, curing leukemias, lymphomas, inherited blood disorders and selected immune and metabolic diseases.
Chinese transplant centers pioneered haplotype-identical (half-matched family donor) transplantation — now standard worldwide — meaning virtually every patient has a potential donor.
Symptoms & Signs
Transplant is a treatment, not a symptom-driven procedure — indications include leukemia in remission with high relapse risk
Relapsed or refractory lymphoma and myeloma after salvage therapy
Severe aplastic anemia with failing marrow
Inherited disorders: thalassemia major, sickle-cell disease, immunodeficiency syndromes
Prior failure of conventional chemotherapy or targeted therapy
Molecular markers — such as persistent minimal residual disease — indicating high risk without transplant
Diagnosis
Full re-staging of the underlying disease before conditioning
HLA typing of patient and potential family donors; unrelated donor registry searches
Donor selection incorporating age, health and matching quality
Comprehensive organ-function assessment: heart, lung, liver, kidney
Infection screening including hepatitis, CMV and respiratory viruses
Fertility-preservation counseling before conditioning begins
Treatment Options
Autologous transplant: the patient’s own stem cells rescue marrow after high-dose therapy
Allogeneic transplant from matched sibling, unrelated or haplotype donors
Reduced-intensity conditioning for older or less-fit patients
Graft-versus-host disease prevention and treatment protocols
Post-transplant immune monitoring and infection prophylaxis
Relapse surveillance with molecular minimal-residual-disease testing
Advanced Technologies & Novel Drug
Haplotype-identical transplant platforms originated at Chinese centers
GMP cell-processing laboratories for graft engineering and manipulation
JAK-inhibitor and post-transplant cyclophosphamide GVHD prophylaxis
Molecular minimal-residual-disease monitoring guiding intervention
Novel post-transplant maintenance agents for relapse prevention
Hospital & Specialist
- Peking University People's Hospital — Beijing
- Hospital of Hematology, Chinese Academy of Medical Sciences — Tianjin
- Ruijin Hospital, affiliated with Shanghai Jiao Tong University School of Medicine — Shanghai
- Peking University First Hospital (PKUHSC) — Beijing
- Shen Zhi Xiang — Hematology
- Xu Ying — Hematology
- Liu Xiao Li — Hematology
- Liu Qi Fa — Hematology